English
Język Polski
Positive impact of tranexamic acid in various medical settings
Katarzyna Herjan
Piotr Armański
Jakub Olszewski
Magdalena Sitnik
Maciej Bara
Abstract
The role of successful hemostasis cannot be overemphasized. Bleeding can occur due to various reasons and its cause is not always evident. Any delay in restoring proper hemostasis is associated with an increased risk of complications and therefore results in increased mortality. Discovered in 1962 by Japanese researchers Shosuke and Utako Okamoto, tranexamic acid (TXA) is an anti-fibrinolytic agent that inhibits plasminogen activation by blocking the lysine binding sites on plasminogen. Thanks to its ability to inhibit fibrinolysis it stabilizes the preformed fibrin mesh-work and has a beneficial effect in reducing blood loss in a wide range of clinical settings. TXA has been shown to reduce the risk of perioperative bleeding in patients undergoing noncardiac surgeries. CRASH (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage) trials provided the largest body of evidence confirming the effectiveness of early administration of TXA, defined as administration within 3 hours after trauma, in reducing mortality in patients with severe injuries and traumatic brain injury. Recent evidence indicates that TXA administration in the treatment of postpartum hemorrhage results in notable mortality reduction. Topical or locally injected tranexamic acid may reduce blood loss with negligible risk of systemic adverse effects. More high-quality studies are needed to determine safety, efficacy, and dosage. The risk of serious adverse events, especially vascular occlusive events, in patients receiving TXA compared to the placebo group did not differ significantly.
Keywords:
tranexamic acid , antifibrinolytic agents , bleeding , traumaMost read articles by the same author(s)
- Katarzyna Kozon, Małgorzata Krzyżanowska, Jakub Olszewski, Andrzej Patyra, Spinal muscular atrophy – the effectiveness of treatment and new therapeutic possibilities for selected groups of patients in Poland , Prospects in Pharmaceutical Sciences: Vol. 21 No. 2 (2023)
- Jakub Olszewski, Katarzyn Kozon, Andrzej Patyra, Flozins in heart failure – a new reimbursement indication , Prospects in Pharmaceutical Sciences: Vol. 20 No. 1 (2022)
- Adam Piasecki, Magdalena Sitnik, Jakub Olszewski, Maciej Bara, Katarzyna Herjan, Piotr Armański, The changing landscape of mineralocorticoid receptor antagonists – finerenone in cardiovascular and renal health , Prospects in Pharmaceutical Sciences: Vol. 22 No. 1 (2024)
- Maciej Bara, Agata Janczak, Toxicity of anesthetic gases: exposure in operating rooms and influence on the environment , Prospects in Pharmaceutical Sciences: Vol. 21 No. 3 (2023)
- Małgorzata Krzyżanowska, Katarzyna Kozon, Jakub Olszewski, Andrzej Patyra, Efficacy of satralizumab therapy in the treatment of NMOSD , Prospects in Pharmaceutical Sciences: Vol. 21 No. 3 (2023)
- Maciej Bara, Jakub Starownik, Jakub Szydło, Patryk Gryszkiewicz, Jakub Nieznański, Dapagliflozin - new solution in chronic kidney disease treatment , Prospects in Pharmaceutical Sciences: Vol. 22 No. 2 (2024)
- Jakub Olszewski, Katarzyna Kozon, Magdalena Sitnik, Katarzyna Herjan, Karolina Mikołap, Bartłomiej Gastoł, Maciej Bara, Piotr Armański, Marcin Sawczuk, Mirikizumab – a new option in the treatment of inflammatory bowel diseases , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)
Similar Articles
- Aleksandra Mikulska, Arkadiusz Kocur, Pharmacotherapy with high doses of methotrexate (HDMTX) in oncology – how should chemotherapy be conducted based on therapeutic drug monitoring? , Prospects in Pharmaceutical Sciences: Vol. 21 No. 4 (2023)
- Falah Saleh Mohammed, İmran Uysal, Mustafa Sevindik, A review on antiviral pants effective against different virus types , Prospects in Pharmaceutical Sciences: Vol. 21 No. 2 (2023)
- Kinga Sosnowicz, Monika Czerwińska, Plant materials used in eye diseases - from use in traditional medicine to research in antioxidant, anti - inflammatory, and antibacterial activity , Prospects in Pharmaceutical Sciences: Vol. 22 No. 3 (2024)
- Grażyna Kubiak-Tomaszewska, Jan Pachecka, Jacek Łukaszkiewicz, Piotr Tomaszewski, MECHANISMS OF RECEPTOR-DEPENDENT REGULATION OF BILE ACID AND XENOBIOTIC METABOLISM. THE ROLE OF CYP3A4 EXPRESSION IN THE SAFETY AND EFFECTIVENESS OF PHARMACOTHERAPY , Prospects in Pharmaceutical Sciences: Vol. 14 No. 9 (2016)
- Natalia Cichoń, Dominika Lach, Michał Bijak Bijak, Paulina Rzeźnicka, Joanna Saluk, SIMILARITIES AND DIFFERENCES IN ANTIPLATELET THERAPY IN ACUTE CORONARY SYNDROMES AND ISCHEMIC STROKE , Prospects in Pharmaceutical Sciences: Vol. 14 No. 4 (2016)
- Jadwiga Turło, FUNGAL BIOTECHNOLOGY. APPLICATIONS IN PHARMACY AND SUPPLEMENTATION , Prospects in Pharmaceutical Sciences: Vol. 11 No. 3 (2013)
- Adam Piasecki, Non-vitamin K antagonist oral anticoagulants (NOAC) in nonvalvular atrial fibrillation – in-group comparison , Prospects in Pharmaceutical Sciences: Vol. 20 No. 1 (2022)
- Piotr Luliński, Dorota Maciejewska, SYNTHESIS OF DOPAMINE-IMPRINTED POLYMERS AND THEORETICAL ANALYSIS OF INTERMOLECULAR INTERACTIONS IN TEMPLATE-MONOMERS , Prospects in Pharmaceutical Sciences: Vol. 6 No. 1 (2008)
- Marta Szymańska, Andrzej Baranowski, Dariusz Płachta, A REVIEW OF THE MOST OFTEN USED MEDICINES IN THE TREATMENT OF FUNGAL INFECTIONS , Prospects in Pharmaceutical Sciences: Vol. 5 No. 1 (2007)
- Bartłomiej Pyrak, Karolina Rogacka, Dariusz Maciej Pisklak, Anti-leukotriene drugs in the therapy of inflammatory diseases , Prospects in Pharmaceutical Sciences: Vol. 20 No. 2 (2022)
You may also start an advanced similarity search for this article.
Details
References
Statistics
Authors
Citation rules
Cited by / Share
Licence
This work is licensed under a Creative Commons Attribution 4.0 International License.